XELJANZ 10 MG
TOFACITINIB (TOFACITINIB CITRATE) : 10 MG · DIN 02480786 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is XELJANZ?
XELJANZ 10 MG contains TOFACITINIB (TOFACITINIB CITRATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02480786, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Jan-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XELJANZ used for?
Treatment of RA, PsA, AS, UC, and pJIA/jPsA (children >=40kg) in patients with inadequate response or intolerance to standard therapies (MTX, DMARDs, or TNF inhibitors).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02480786 |
|---|---|
| Brand name | XELJANZ |
| Generic / active ingredient | TOFACITINIB (TOFACITINIB CITRATE) : 10 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AF01 TOFACITINIB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-Jan-2019 |
How is it administered?
RA/PsA/AS: 5 mg BID (or 11 mg XR QD for RA). UC: 10 mg BID induction (8-16 weeks), then 5 mg or 10 mg BID maintenance. JIA (>=40kg): 5 mg BID. Take with or without food. Swallow XR tablets whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (Section 11 header present but content cut off), typically 15-30°C.
How is it supplied?
5 mg and 10 mg: HDPE bottles of 60 or foil blisters of 56. 11 mg XR: HDPE bottles with desiccant.
Contraindications
Known hypersensitivity to tofacitinib or any ingredient; severe hepatic impairment; during pregnancy and breastfeeding.
Warnings and precautions
Serious infections (TB, fungal, viral), malignancies (lymphoma, lung cancer), thrombosis (PE, DVT), and major adverse cardiovascular events (MACE). Monitor ANC, ALC, and Hemoglobin.
What can be used instead?
Other Canadian products sharing ATC code L04AF01 TOFACITINIB. 12 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-TOFACITINIB | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02530015 |
| AURO-TOFACITINIB | 5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02530007 |
| JAMP TOFACITINIB | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02522896 |
| PMS-TOFACITINIB | 5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02522799 |
| SANDOZ TOFACITINIB | 10 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02551705 |
| SANDOZ TOFACITINIB | 5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02551691 |
| TARO-TOFACITINIB | 10 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02511312 |
| TARO-TOFACITINIB | 5 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02511304 |
| TARO-TOFACITINIB XR | 11 MG | TABLET (EXTENDED-RELEASE) | TARO PHARMACEUTICALS INC | MARKETED | DIN 02553988 |
| XELJANZ | 5 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02423898 |
Who else supplies TOFACITINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TOFACITINIB appears in 72 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.